DK0414607T3 - Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf - Google Patents

Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf

Info

Publication number: DK0414607T3
Authority: DK; Denmark
Prior art keywords: sense oligonucleotide; tnf; medicament; manufacture; well
Prior art date: 1989-08-23

Application number

DK90402329.8T

Other languages

English (en)

Inventor

Pierre Smets

Abdel Karim Braham

Rene Zalisz

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-23

Filing date

1990-08-22

Publication date

1995-06-06

1990-08-22 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1995-06-06 Application granted granted Critical

1995-06-06 Publication of DK0414607T3 publication Critical patent/DK0414607T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
239000005864 Sulphur Substances 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
229920000729 poly(L-lysine) polymer Polymers 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K2203/00—Specific aspects not provided for in the other groups of this subclass relating to the windings
- H02K2203/03—Machines characterised by the wiring boards, i.e. printed circuit boards or similar structures for connecting the winding terminations

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Silver Salt Photography Or Processing Solution Therefor (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Thin Magnetic Films (AREA)

DK90402329.8T 1989-08-23 1990-08-22 Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf DK0414607T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8911171A FR2651130B1 (fr)	1989-08-23	1989-08-23	Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.

Publications (1)

Publication Number	Publication Date
DK0414607T3 true DK0414607T3 (da)	1995-06-06

Family

ID=9384878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90402329.8T DK0414607T3 (da)	1989-08-23	1990-08-22	Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf

Country Status (19)

Country	Link
US (1)	US5705389A (da)
EP (1)	EP0414607B1 (da)
JP (1)	JPH0391485A (da)
KR (1)	KR0151153B1 (da)
CN (1)	CN1028760C (da)
AT (1)	ATE120201T1 (da)
AU (1)	AU642423B2 (da)
CA (1)	CA2023899C (da)
DE (1)	DE69017983T2 (da)
DK (1)	DK0414607T3 (da)
ES (1)	ES2069715T3 (da)
FR (1)	FR2651130B1 (da)
GR (1)	GR3015527T3 (da)
HU (1)	HU215242B (da)
IE (1)	IE68592B1 (da)
IL (1)	IL95342A (da)
PT (1)	PT95067B (da)
RU (1)	RU2066325C1 (da)
ZA (1)	ZA906675B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1250722B (it) *	1991-07-30	1995-04-21	Univ Degli Studi Milano	Oligonucleotidi antisenso
TW323284B (da) *	1992-03-23	1997-12-21	Novartis Ag
CA2155103A1 (en) *	1993-02-03	1994-08-18	Rudolph Lucas	Tnf-alpha muteins and a process for preparing them
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
AU1249299A (en) *	1997-11-25	1999-06-15	Brax Genomics Limited	Chimeric antisense oligonucleotides against tnf-alpha and their uses
US20020077276A1 (en) *	1999-04-27	2002-06-20	Fredeking Terry M.	Compositions and methods for treating hemorrhagic virus infections and other disorders
US20040006036A1 (en) *	2000-04-12	2004-01-08	Gmr, A Delaware Corporation	Silencing transcription by methylation
CA2817619A1 (en) *	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) *	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
SI1944322T1 (sl) *	2002-07-19	2015-06-30	Abbvie Biotechnology Ltd.	Zdravljenje s TNP alfa povezanih bolezni
EP1807111A4 (en) *	2004-10-08	2009-05-27	Abbott Biotech Ltd	SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
MX2007014440A (es)	2005-05-16	2008-02-11	Abbott Biotech Ltd	Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
US20070041905A1 (en) *	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
EP2007426A4 (en)	2006-04-10	2010-06-16	Abbott Biotech Ltd	COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
EP2010214A4 (en)	2006-04-10	2010-06-16	Abbott Biotech Ltd	USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US20080118496A1 (en) *	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en)	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
US20080131374A1 (en) *	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
CN101235064B (zh) *	2008-02-27	2011-08-10	东南大学	可脱保护的硫代核苷酸单体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0090789A1 (en) *	1982-03-26	1983-10-05	Monsanto Company	Chemical DNA synthesis
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
FR2584090B1 (fr)	1985-06-27	1987-08-28	Roussel Uclaf	Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
WO1988006625A2 (en) *	1987-02-26	1988-09-07	Cetus Corporation	Arginine-depleted human tumor necrosis factor
ATE137806T1 (de) *	1988-07-05	1996-05-15	Baylor College Medicine	Verfahren zur identifizierung von bakterien

1989
- 1989-08-23 FR FR8911171A patent/FR2651130B1/fr not_active Expired - Fee Related
1990
- 1990-08-10 IL IL9534290A patent/IL95342A/en unknown
- 1990-08-22 DK DK90402329.8T patent/DK0414607T3/da active
- 1990-08-22 AT AT90402329T patent/ATE120201T1/de not_active IP Right Cessation
- 1990-08-22 KR KR1019900013041A patent/KR0151153B1/ko not_active Expired - Lifetime
- 1990-08-22 EP EP90402329A patent/EP0414607B1/fr not_active Expired - Lifetime
- 1990-08-22 ES ES90402329T patent/ES2069715T3/es not_active Expired - Lifetime
- 1990-08-22 AU AU61190/90A patent/AU642423B2/en not_active Expired
- 1990-08-22 PT PT95067A patent/PT95067B/pt not_active IP Right Cessation
- 1990-08-22 DE DE69017983T patent/DE69017983T2/de not_active Expired - Lifetime
- 1990-08-22 IE IE303690A patent/IE68592B1/en not_active IP Right Cessation
- 1990-08-22 ZA ZA906675A patent/ZA906675B/xx unknown
- 1990-08-23 CN CN90107162A patent/CN1028760C/zh not_active Expired - Lifetime
- 1990-08-23 HU HU905302A patent/HU215242B/hu unknown
- 1990-08-23 JP JP2220177A patent/JPH0391485A/ja active Pending
- 1990-08-23 CA CA002023899A patent/CA2023899C/fr not_active Expired - Lifetime
1991
- 1991-12-24 RU SU915010468A patent/RU2066325C1/ru active
1994
- 1994-11-18 US US08/342,338 patent/US5705389A/en not_active Expired - Lifetime
1995
- 1995-03-23 GR GR940401796T patent/GR3015527T3/el unknown

Also Published As

Publication number	Publication date
DE69017983T2 (de)	1995-09-28
US5705389A (en)	1998-01-06
FR2651130A1 (fr)	1991-03-01
IL95342A (en)	1995-01-24
HUT56113A (en)	1991-07-29
KR0151153B1 (ko)	1998-08-17
EP0414607A2 (fr)	1991-02-27
PT95067A (pt)	1991-04-18
FR2651130B1 (fr)	1991-12-13
IL95342A0 (en)	1991-06-30
HU905302D0 (en)	1991-02-28
CA2023899C (fr)	2002-05-14
CN1028760C (zh)	1995-06-07
KR910004198A (ko)	1991-03-28
ES2069715T3 (es)	1995-05-16
AU642423B2 (en)	1993-10-21
IE68592B1 (en)	1996-06-26
AU6119090A (en)	1991-02-28
EP0414607A3 (en)	1991-04-03
GR3015527T3 (en)	1995-06-30
IE903036A1 (en)	1991-02-27
CN1049668A (zh)	1991-03-06
RU2066325C1 (ru)	1996-09-10
EP0414607B1 (fr)	1995-03-22
DE69017983D1 (de)	1995-04-27
ZA906675B (en)	1991-10-30
HU215242B (hu)	1998-11-30
JPH0391485A (ja)	1991-04-17
PT95067B (pt)	1997-05-28
ATE120201T1 (de)	1995-04-15
CA2023899A1 (fr)	1991-02-24

Publication	Publication Date	Title
DK0414607T3 (da)	1995-06-06	Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf
DE3280400D1 (de)	1992-06-04	Oligonukleotides heilmittel und dessen herstellungsverfahren.
KR960700062A (ko)	1996-01-19	산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH)
IL113519A (en)	1997-11-20	Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage, their preparation and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides
ATE328074T1 (de)	2006-06-15	Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
FR2656609B1 (fr)	1992-03-27	Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
PT92303A (pt)	1990-05-31	Processo para a preparacao de derivados de xantina
DK165744C (da)	1993-06-07	Thienopyrimidinderivater, fremgangsmaader til fremstilling deraf og farmaceutiske praeparater
EP1122252A4 (en)	2002-06-26	CONDENSED HEREROCYCLIC NITROGEN COMPOUNDS; MANUFACTURING PROCESS AND AGENTS CONTAINING THEM
FI913713A0 (fi)	1991-08-05	Nya bicykliska aminosubstituerade foereningar.
ZA889521B (en)	1990-08-29	Polystyrene polymers and their use as cholesterol lowering agents
IL81752A (en)	1991-01-31	Nitrogen containing heterocyclic isohexide derivatives,processes for their preparation and pharmaceutical compositions containing them
IL89185A0 (en)	1989-09-10	Basic-substituted 5-halo-thieno-sothiazol-3-(2h)-one 1,1-dioxides,their preparation and pharmaceutical compositions containing them
HUP0105235A2 (hu)	2002-04-29	Az N-terminálison szubsztituált benzilcsoportot tartalmazó bisz-aminosav szulfonamidok mint HIV proteáz inhibitorok, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
IT1222414B (it)	1990-09-05	Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
GB8608893D0 (en)	1986-05-14	D-nor-7-ergoline derivatives
EP0204172A3 (en)	1987-09-30	Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use
TH4444A (th)	1987-10-01	อนุพันธ์ใหม่ของเบนซิมิดาโซลที่ทำให้เสถียรขึ้น
IT1173550B (it)	1987-06-24	Sale di eritromicina con attivita'mucosecretolitica e fluidificante, processo per la sua preparazione e sue composizioni farmaceutiche